# Natera, Inc.  Share Price Target ‘$123.41’, now 10.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/natera-inc.share-price-target-123.41-now-10.5-upside-potential/4121163932
- Published: 2024-07-05T16:22:29+01:00
- Author: Charlotte Edwards

**Natera, Inc.** which can be found using ticker (NTRA) have now 17 confirmed analysts
covering the stock with the consensus suggesting a rating of ‘buy’. The range between
the high target price and low target price is between $160.00 and $37.00 calculating
the average target share price we see $123.41. (at the time of writing). Given that
the stocks previous close was at $111.64 this indicates there is a potential upside
of 10.5%. The 50 day moving average now sits at $105.00 while the 200 day moving
average is $74.67. The market capitalization for the company is 13.76B. The stock
price is currently at: $112.04 USD

 The potential market cap would be $15,208,740,012 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $10.31 and
a -17.14% return on assets.

Natera, Inc. is a diagnostics company that is focused on the development and commercialization
of molecular testing services, applying its technology in the fields of women’s 
health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology
combines its molecular assays, which reliably measure many informative regions across
the genome from samples as small as a single cell. The Company’s product offerings
include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening(
HCS), Spectrum Preimplantation Genetics, Anora Miscarriage Test (Anora) and Prospera.
The Company also offers Constellation, a cloud-based software platform that enables
laboratory customers to gain access through the cloud to the Company’s algorithms
and bioinformatics in order to validate and launch tests based on the Company’s 
technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as
in twin pregnancies, typically with a blood draw from the mother.

Share on: